All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced mGC or mGEJC, nivolumab alone vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ATTRACTION-2 (Kang), 2017 0.63 [0.51; 0.78]
0.63 [0.51 ; 0.78 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable deaths (OS) (extension)detailed results ATTRACTION-2 (Kang), 2017 0.62 [0.51; 0.76]
0.62 [0.51 ; 0.76 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable PFS (extension)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
0.60 [0.48 ; 0.74 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable progression or deaths (PFS)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
0.60 [0.48 ; 0.74 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable DCRdetailed results ATTRACTION-2 (Kang), 2017 1.99 [1.24; 3.18]
1.99 [1.24 ; 3.18 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable objective responses (ORR)detailed results Out of scale ATTRACTION-2 (Kang), 2017 34.90 [2.12; 573.88]
34.90 [2.12 ; 573.88 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable AE (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.93 [1.10; 3.38]
1.93 [1.10 ; 3.38 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.75; 1.62]
1.10 [0.75 ; 1.62 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.37; 1.12]
0.65 [0.37 ; 1.12 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.93 [0.45; 1.92]
0.93 [0.45 ; 1.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.69 [0.29; 1.66]
0.69 [0.29 ; 1.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.75 [0.52; 1.10]
0.75 [0.52 ; 1.10 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.92 [0.61; 1.40]
0.92 [0.61 ; 1.40 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable STRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.13 [0.96; 4.71]
2.13 [0.96 ; 4.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable STRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.67 [0.90; 7.91]
2.67 [0.90 ; 7.91 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable TRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.05 [1.36; 3.09]
2.05 [1.36 ; 3.09 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.53 [1.09; 5.83]
2.53 [1.09 ; 5.83 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable TRAE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 1.22 [0.23; 6.37]
1.22 [0.23 ; 6.37 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable TRAE leading to discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.33; 3.63]
1.10 [0.33 ; 3.63 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
0.65 [0.14 ; 2.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Colitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
1.96 [0.22 ; 17.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
1.96 [0.09 ; 43.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.48 [0.07; 3.47]
0.48 [0.07 ; 3.47 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increase AST TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
1.96 [0.09 ; 43.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Nausea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Abdominal pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.14 [0.43; 3.04]
1.14 [0.43 ; 3.04 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Anaemia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.97 [0.54; 1.75]
0.97 [0.54 ; 1.75 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Asthenia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.48 [0.54; 11.47]
2.48 [0.54 ; 11.47 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Back pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.73 [0.12; 4.41]
0.73 [0.12 ; 4.41 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Constipation AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Decreased appetite AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.54 [0.20; 1.42]
0.54 [0.20 ; 1.42 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Diarrhoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
1.96 [0.22 ; 17.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspepsia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspnoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
1.96 [0.09 ; 43.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Fatigue AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.29 [0.07; 1.21]
0.29 [0.07 ; 1.21 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increase AST AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.48 [0.47; 4.67]
1.48 [0.47 ; 4.67 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increased ALT AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.31 [0.34; 5.00]
1.31 [0.34 ; 5.00 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Nausea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.24 [0.02; 2.68]
0.24 [0.02 ; 2.68 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pruritus AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pyrexia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.47 [0.15; 14.22]
1.47 [0.15 ; 14.22 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
0.65 [0.14 ; 2.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Weight decreased AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 21:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 360,719,721,720